Journal article
The role of the adenosine system in epilepsy and its comorbidities
JA Baltos, PM Casillas-Espinosa, B Rollo, KJ Gregory, PJ White, A Christopoulos, P Kwan, TJ O'Brien, LT May
British Journal of Pharmacology | Published : 2024
DOI: 10.1111/bph.16094
Abstract
Epilepsy is one of the most serious and common chronic neurological conditions, characterised by recurrent hypersynchronous electrical activity in the brain that lead to seizures. Despite over 50 million people being affected worldwide, only ~70% of people with epilepsy have their seizures successfully controlled with current pharmacotherapy, and many experience significant psychiatric and physical comorbidities. Adenosine, a ubiquitous purine metabolite, is a potent endogenous anti-epileptic substance that can abolish seizure activity via the adenosine A1 G protein-coupled receptor. Activation of A1 receptors decreases seizure activity in animal models, including models of drug-resistant ep..
View full abstractRelated Projects (2)
Grants
Awarded by Monash University
Funding Acknowledgements
Medical Research Future Fund (MRFF), Grant/Award Numbers: MRF1201781, MRF2015957; National Health and Medical Research Council, Grant/Award Numbers: 1087172, 1145420, 1147291, 1150083, 2013629; National Heart Foundation of Australia Future Leader Fellowship, Grant/Award Number: 101857; Department of Defense USA Epilepsy Research Program, Grant/Award Number: EP200022